Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioArctic AB
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period…
In the wake of multiple recent drug failures in the Alzheimer's sector, Eisai and partner Biogen announce "impressive" top-line results for an amyloid-targeting antibody that provide important support for the amyloid hypothesis and may also bode well for the companies' lead candidate in the same class.
Market Intel: Rivals Catching Up To Intuitive Surgical In Fast-Growing, Fast-Innovating Robotic-Assisted Devices Market
The global market for robotically assisted systems (RAS) is expected to reach $5.3bn by 2021, a CAGR of 11.7%. Meddevicetracker expects this hot market, long-dominated by Intuitive Surgical's da Vinci systems, to see rising competition from innovative companies developing robotic systems that are smaller, portable and less costly and offer surgeons innovative features that allow them to perform even more precise and user-friendly, complex surgeries. In this feature, we'll take a closer look at the overall market, highlighting the competitive landscape as well as limiters and growth opportunities. We'll also take a deep dive into RAS systems and their applications. Surgeons of various specialties provide key insights about the pros and cons of different systems.
- Other Names / Subsidiaries
- BioArctic Neuroscience AB